Shares of gene editing companies dropped on Friday as Wall Street reacted to Intellia Therapeutics' (NASDAQ:NTLA) plans to ...

Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of ...

Wells Fargo lowered the firm’s price target on Intellia Therapeutics (NTLA) to $60 from $70 and keeps an Overweight rating on ...

Ark Invest, led by Cathie Wood, made significant trades in 5 companies on Friday: RXRX, ILMN, NTLA, NET, and ADPT.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

BMO Capital lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $70 and keeps an Outperform rating on the shares. The ...

According to Benzinga Pro, Intellia Therapeutics's peer group average for short interest as a percentage of float is 14.00%, which means the company has more short interest than most of its peers. Did ...

Shares of Intellia Therapeutics, Inc. NTLA were down in pre-market trading on Jan. 10 after the company announced a strategic ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

Just two weeks into 2025, January is proving why it’s earned a reputation as the worst month for layoffs. | Just two weeks ...

The stock market will put aside all fears about tariffs and valuations this morning. The job data in December, released by the Bureau of Labor Statistics will give investors a clue on the U.S. economy ...